AB1203 BURDEN DISEASE OF RHEUMATOID ARTHRITIS IN COLOMBIA, 2015
Authors: Francy Cuervo, Ana María Santos, Ignacio Angarita, Juan Camilo Rueda, Rodrigo Giraldo, Jesús G. Ballesteros, Ingris Peláez-Ballestas, Diana Díaz-Jiménez, Pedro Santos-Moreno, Diana Padilla-Ortiz, Viviana Reyes, Carlos Castañeda-Orjuela, John Londono
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> The prevalence of rheumatoid arthritis (RA) in Colombia according to the COPCORD study was 1.49%. The disease burden data available in our country are based on the results of the Global Burden Disease study (GBD) of 2016. However, the GBD study takes reference data from non-Colombian residents that was extrapolated to our population, given the absence of demographic data at that moment. <h3>Objectives:</h3> To estimate the disease burden of RA for 2015 <h3>Methods:</h3> A descriptive study was developed. The reference data of the population was taken by DANE (Departamento Administrativo Nacional de Estadistica) and the WHO (World Health Organization). The GBD disability definitions were adapted from individual questions of functionality and quality of life questionnaires of the COPCORD study in Colombia (1). A Markov model was developed to calculate the years of life lost due to premature mortality (YLL), years lived with disability (YLD) and Disability-Adjusted Life Year (DALY). <h3>Results:</h3> The distribution of cases by age and severity levels of RA are shown in figure 1 and 2 respectively. Since direct death due to RA were not registered according to the search of the ICD-10 codes in DANE, the YLL was 0. The YLDs in total were 118,358. The DALYs were 118,358 for a rate of 361.54 per 100,000, which is higher than the GBD 2016 results (60 per 100.000). <h3>Conclusion:</h3> The burden disease of rheumatoid arthritis is higher than that referred by GBD. Holistic approaches are required to reduce these parameters of impact on the public health of Colombians. Our data on DALYs usefulness lies in the urgent need for an early diagnosis, to reduce disability and thereby improve the quality of life of patients. Even though, RA was not the registered primary cause of death, it is necessary to explore mortality-associated conditions due to this rheumatic disease. <h3>References</h3> [1] Londono J, Peláez I, Cuervo F, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD-Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Rev Colomb Reum [Internet]. 2018;1–12. Available from: https://doi.org/10.1016/j.rcreu.2018.08.003 <h3>Disclosure of Interests:</h3> Francy Cuervo: None declared, Ana María Santos: None declared, Ignacio Angarita: None declared, Juan Camilo Rueda: None declared, Rodrigo Giraldo: None declared, Jesús G Ballesteros: None declared, Ingris Peláez-Ballestas: None declared, Diana Díaz-Jiménez: None declared, Pedro Santos-Moreno Grant/research support from: Dr Santos has received research grants from Janssen, Abbvie and UCB, Speakers bureau: Dr Santos has received speaker fees from Sanofi, Lilly, Bristol, Pfizer, Abbvie, Janssen and UCB, Diana Padilla-Ortiz: None declared, Viviana Reyes: None declared, Carlos Castañeda-Orjuela: None declared, John Londono: None declared